Gurgaon Samachar

Acute Myocardial Infarction Market

The “Acute Myocardial Infarction Market Report” by DelveInsight offers a robust analysis of market size, treatment algorithms, and unmet needs across the 7MM, providing stakeholders with actionable insights to navigate a highly competitive and evolving cardiovascular space.

Some of the Key Facts of the Acute Myocardial Infarction Market Report:

• The AMI market in the 7MM is valued at USD 1.6 billion in 2023, with expected strong growth.

• In 2023, the U.S. had ~823K incident AMI cases, projected to rise by 2034.

• LODOCO, FDA-approved by AGEPHA Pharma, is the first treatment targeting residual inflammatory risk in cardiovascular disease.

• NSTEMI cases (~607K) outnumbered STEMI cases in the U.S. in 2023.

• In March 2025, Powerful Medical, a leader in AI-driven cardiovascular diagnostics, announced that its PMcardio STEMI AI ECG model has received Breakthrough Device Designation from the FDA. This recognition highlights PMcardio’s innovation in detecting ST-elevation myocardial infarction (STEMI) and STEMI equivalents, conditions that require urgent intervention.

• In September 2024, GE HealthCare (Nasdaq: GEHC) announced FDA approval of FLYRCADO (flurpiridaz F 18), the first positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD). Flyrcado offers superior diagnostic efficacy compared to the widely used single-photon emission computed tomography (SPECT) MPI, enhancing access to PET MPI and improving accuracy, particularly in challenging cases like high BMI patients and women.

• Emerging acute myocardial infarction drugs include Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.

• Leading companies in the acute myocardial infarction market include Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.

To know in detail about the acute myocardial infarction market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Acute Myocardial Infarction Market Forecast

Acute Myocardial Infarction Overview

Acute Myocardial Infarction (AMI) refers to the death of heart muscle tissue due to the sudden blockage of a coronary artery. Common symptoms include chest pain, shortness of breath, nausea, and sweating. Diagnosis is based on electrocardiogram (ECG) findings and cardiac biomarkers. Treatment typically involves antiplatelet and anticoagulant medications, nitrates, beta-blockers, statins, and timely reperfusion therapies. In ST-segment elevation myocardial infarction (STEMI), emergency reperfusion is achieved through fibrinolytics, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). In non-ST-segment elevation myocardial infarction (NSTEMI), PCI or CABG is also used.

AMI remains a leading cause of mortality in developed nations and is classified into two main types: STEMI and NSTEMI. While unstable angina shares similarities with NSTEMI, it does not show elevated cardiac biomarkers.

Get a free sample of the acute myocardial infarction market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market

Acute Myocardial Infarction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Myocardial Infarction Epidemiology Segmentation:

The Acute Myocardial Infarction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Incident Cases of AMI

• Type-Specific Incident Cases of AMI

• Gender-Specific Incident Cases of AMI

Download the report to understand which factors are driving acute myocardial infarction epidemiology trends @ Acute Myocardial Infarction Epidemiology Forecast

Acute Myocardial Infarction Drugs Uptake, and Pipeline Development Activities

The acute myocardial infarction drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the acute myocardial infarction market or expected to be launched during the study period. The analysis covers the acute myocardial infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the acute myocardial infarction pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Myocardial Infarction Market Strengths

• Strong pipeline with innovative therapies targeting inflammation, thrombosis, and cardiac repair.

• High disease burden and awareness ensure steady demand for treatment and care.

Acute Myocardial Infarction Market Weaknesses

• High treatment costs limit access in low- and middle-income regions.

• Delayed diagnosis and limited emergency care affect outcomes in underserved areas.

Scope of the Acute Myocardial Infarction Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Acute Myocardial Infarction Therapies: Selatogrel, Dutogliptin, Olpasiran, FDY-5301, Ziltivekimab, Milvexian, Zalunfiban, KAND567, ProtheraCytes, and others.

• Key Acute Myocardial Infarction Companies: Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen and Arrowhead Pharmaceuticals, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera and BioCardia, Mesoblast, Boehringer Ingelheim, and others.

• Acute Myocardial Infarction Therapeutic Assessment: Acute myocardial infarction, currently marketed, and acute myocardial infarction emerging therapies

• Acute Myocardial Infarction Market Dynamics: Acute myocardial infarction market drivers and Acute Myocardial Infarction market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Acute Myocardial Infarction Unmet Needs, KOL’s views, Analyst’s views, Acute Myocardial Infarction Market Access and Reimbursement

To learn more about the key players and advancements in the acute myocardial infarction treatment landscape, visit the Acute Myocardial Infarction Market Analysis Report

Table of Contents

1. Acute Myocardial Infarction Market Report Introduction

2. Executive Summary for Acute Myocardial Infarction

3. SWOT analysis of Acute Myocardial Infarction

4. Acute Myocardial Infarction Patient Share (%) Overview at a Glance

5. Acute Myocardial Infarction Market Overview at a Glance

6. Acute Myocardial Infarction Disease Background and Overview

7. Acute Myocardial Infarction Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Myocardial Infarction

9. Acute Myocardial Infarction Current Treatment and Medical Practices

10. Acute Myocardial Infarction Unmet Needs

11. Acute Myocardial Infarction Emerging Therapies

12. Acute Myocardial Infarction Market Outlook

13. Country-Wise Acute Myocardial Infarction Market Analysis (2020–2034)

14. Acute Myocardial Infarction Market Access and Reimbursement of Therapies

15. Acute Myocardial Infarction Market Drivers

16. Acute Myocardial Infarction Market Barriers

17. Acute Myocardial Infarction Appendix

18. Acute Myocardial Infarction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/